WO2003008965A1 - Metodo de deteccion y evaluacion de compuestos mimeticos de paclitaxel - Google Patents
Metodo de deteccion y evaluacion de compuestos mimeticos de paclitaxel Download PDFInfo
- Publication number
- WO2003008965A1 WO2003008965A1 PCT/ES2002/000262 ES0200262W WO03008965A1 WO 2003008965 A1 WO2003008965 A1 WO 2003008965A1 ES 0200262 W ES0200262 W ES 0200262W WO 03008965 A1 WO03008965 A1 WO 03008965A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- paclitaxel
- microtubules
- probe
- flutax
- binding
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Definitions
- Anti-tumor agents Homogeneous high performance assay for the detection of substances that can replace paclitaxel at its binding site in microtubules and therefore with potential activity as antitumor agents.
- Paclitaxel (Taxol ®), a compound widely used in cancer chemotherapy, presents as other anticancer agents, side effects. This diterpenoid compound was originally extracted from the bark of a plant, Taxus brevifolia, of slow growth, which led to a problem of lack of a cheap and available source of paclitaxel.
- the paclitaxel currently used is a semi-synthesis product from a precursor extracted from the yew leaf.
- paclitaxel presents problems of extreme insolubility. Therefore, although paclitaxel is a chemotherapeutic agent with a very important biological activity, the discovery of new sources of paclitaxel or paclitaxel mimetic compounds has a decisive utility.
- Paclitaxel promotes the assembly of ⁇ -tubulin in microtubules by preferential binding to assembled tubulin rather than to non-assembled tubulin. Its effect is related to that of the GTP nucleotide, with important differences.
- the GTP is attached to one end of the tubulin dimer making contact with the next dimer along each protofilament that forms the microtubule, while the paclitaxel is attached to one side of ⁇ -tubulin near the contact with the next protofilament; in the ⁇ -tubulin, the area corresponding to the paclitaxel binding cavity is occupied by a loop of the peptide chain (Nogales, E.).
- Unassembled tubulin dimers bind GTP and the binding site is occluded by the assembly, while the paclitaxel binding site exists only in assembled tubulin.
- GTP hydrolysis allows disassembly and regulation of the microtubule system, however, the activation of tubulin by paclitaxel is permanent, stabilizing the microtubules.
- paclitaxel The suppression of cell microtubule dynamics by paclitaxel is a leading cause of inhibition of cell division and death of tumor cells (Jordan, MA and Wilson, L.).
- a number of diverse natural substances, including epothilones (Bollag, DM et al), discodermolide (Ter Haar, E. et al), eleuterobin (Long, BH et al), and laulimalide (Mooberry, Sl et al) mimic the cytotoxic effects of paclitaxel, apparently joining its site in microtubules.
- epothilones Bollag, DM et al
- discodermolide Ter Haar, E. et al
- eleuterobin Long, BH et al
- laulimalide Mooberry, Sl et al
- Luminescence based methods are very useful for these purposes.
- the fluorescent, water-soluble and active derivatives of paclitaxel bound with an alanine intermediate in the nonessential position 7 are specific probes of the paclitaxel binding site to the microtubules (Evangelio, J.A., et al).
- These fluorescent taxoids have been used primarily to locate subcellular sites of cytotoxic taxoid binding to microtubules of the spindle pole and centrosomes (Abal, MA, et al), as well as to measure rapid binding and dissociation kinetics of the paclitaxel site, which is exposed in microtubules (D ⁇ az, JF, et al).
- the primary object of this invention is the development of a homogeneous fluorescent assay of ligand binding to the paclitaxel site in the microtubules, which allows high-performance detection of new paclitaxel mimetics.
- the method is based on the combination of two components, a target and a probe.
- the target consists of in vitro assembled microtubules which are stabilized by chemical crosslinking and stored in liquid nitrogen. This method of conservation is novel.
- Paclitaxel fluorescent derivatives are used as probes, which specifically bind to microtubules (patents ES 2121549, ES 2105983, W09719938, Higher Council for Scientific Research) (Diaz, JF, et al).
- the applications of this method are: search for new antitumor agents from libraries of natural and synthetic extracts and compounds; evaluation of chemical modifications of series of existing compounds (including paclitaxel, epothilone, discodermolide, euterobine, laulimalide); content assessment of active taxanes in natural sources; Biological and cancer research. DESCRIPTION OF THE INVENTION Brief description of the invention
- the microtubule paclitaxel binding site also binds other recently discovered ligands with antitumor activity.
- a high performance homogeneous assay for the detection of paclitaxel biomimetics has been designed, based on the displacement of the fluorescent taxoid 7-0- [N- (2,7-difluoro-4'-fluorescecarbonyl) - L-alanyl] Paclitaxel from its binding site in dilute solutions of conserved microtubules.
- the method of detection, object of the present invention and which is claimed is based on the combination of the two components, the target, which consists of in vitro assembled microtubules that are stabilized by chemical cross-linking and stored indefinitely frozen in liquid nitrogen. Until its use, this method of preserving the microtubules is also claimed in the present invention, and the probe, which consists of said fluoresceinated paclitaxel derivative that specifically binds to the microtubules.
- the method consists in adding the substances to be tested (non-fluorescent) to multiple aliquots of a diluted solution of the target and the probe in multiwell microplates.
- the substances to be tested may be the compounds of the families of discodermolide, eleutherobin, sarcodicitin, epothilones and paclitaxel.
- This method also has application to measure active paclitaxel-like contents from natural sources and for the high-performance detection of new paclitaxel biomimetics.
- the target-bound probe has a fluorescence anisotropy value much greater than that of the free probe; Displacement by any competing substances of the interaction of the probe (reference ligand) with the target is detected by measuring the decrease in anisotropy of the fluorescence of the probe with a fluorescence polarization reader in microplates.
- RET resonant energy transfer
- fluorescence probe 7-0- [N- (4'-fluoresceincarbonyl) -L-alanyl-] Paclitaxel This method has application in the development of tools for conducting tests in cancer and / or biological research.
- the method of preserving the microtubules indefinitely is also an object of the present invention. This method consists of dialyzing the cross-linked microtubules against a preservation buffer and cryopreserving them.
- microtubules bind to Paclitaxel and Flutax with high affinity, low concentrations of binding sites are needed in order to detect competitors of lower affinity. These dilution stabilized binding sites were provided by gently cross-linked microtubules (see Example; Gospel, J.A. et al .; Diaz, J.F. et al.).
- Both the negative anisotropy of the 329nm band and the positive anisotropy of the lower energy excitation transition (495nm) of the difluoro-fluorescein are specifically enhanced by binding of Flutax-2 to microtubules.
- the binding of Flutax-2 at these concentrations is completely annulled by 10 ⁇ M paclitaxel.
- Flutax- 2 can be considered a genuine microtubule paclitaxel binding site probe. Validation of the probe and target.
- Fluorescent assay for the detection and evaluation of pandoids that interact with the paclitaxel binding site in the microtubules.
- Flutax-2 as a reference probe of the paclitaxel binding site
- the binding of other non-fluorescent ligands that displace Flutax-2 from the microtubules can be easily measured by changes in their own fluorescence properties in a competition rehearsal The change in fluorescence anisotropy has been used, which was analyzed in 96-well plates with a microplate reader.
- Figure 2 shows how paclitaxel and docetaxel effectively decrease fluorescence anisotropy of 50nM Flutax-2 solutions - 50nM microtubule sites.
- Baccatina III is equivalent to the taxane ring system, in which the C-13 OH group replaces the paclitaxel side chain (see chemical structures in Fig. 2).
- the C-13 side chain has previously been considered a determinant essential for paclitaxel recognition, however, the methyl ester of the C-13 side chain was, within its solubility limit, inactive to displace Flutax-2.
- Taxane-specific monoclonal antibodies offer possibly unsurpassed sensitivity for the determination of drug contents and closely related compounds (Grothaus, PG, et al .; O'Boyle, KP; Bicamumpaka, C. and Page, M.), however, they may fail to recognize non-chemically related ligands of the microtubule paclitaxel binding site.
- this assay is a useful tool for the evaluation of the binding affinity of newly designed compounds of the discodermolide, eleutherobin, epothilones and paclitaxel families. It is also applicable to the measurement of active paclitaxel-like contents from natural sources, and for the high-performance investigation of new paclitaxel biomimetics, in a complementary way to cellular scans for mitotic inhibitors, such as those used in the discovery of monastrol (Mayer , TU, et al.).
- An interesting property of the fluorescence anisotropy assay is its sensitivity for the detection of medium affinity ligands.
- FIGURE 1 A fluorescence micrograph of a typical reaction mixture used in this invention, consisting of stabilized microtubules (100nM taxoid sites) and Flutax-2 fluorescent taxoid (100nM). The bar indicates 10 ⁇ m.
- FIGURE 2 Competition isotherms of ligands that bind to the microtubule paclitaxel site in GAB-GDP buffer at 25 ° C. Fluorescence anisotropy of multiple 50nM Flutax-2 solutions and 50nM microtubule binding sites with various concentrations of competitors was measured in duplicate, using a microplate reader. Solid circles, paclitaxel (1); the empty circles, docetaxel; the squares, baccatina lll (2), the triangles, methyl ester of the C-13 side chain of paclitaxel (3); the crosses, corresponding controls with 1% DMSO (v / v) without ligand.
- EXAMPLE OF EMBODIMENT OF THE INVENTION 1. Taxoids. Fluorescent probe Concentrated series solutions were prepared and kept at -20 C in a dry environment. Paclitaxel (from the National Cancer Institute, Bethesda, MD) was measured spectrophotometrically at 273 nm after dilution in methanol, using an extinction coefficient of 1,700 M "1 cm " 1 (Diaz, JF and Andreu, JM). 3 H-Paclitaxel (4 Ci mmol "1 ) was obtained from Moravek Biochemicals (Brea, CA). Docetaxel (Taxotere) was provided by Rhóne-Poulenc Rorer (Antony, France).
- Baccatina III was obtained from Sigma; it was found devoid of HPLC impurities (a 20-80% gradient of acetonitrile in 0.05% aqueous trifluoroacetic acid, on a C-18 column, monitored at 228 nm). A baccatin III extinction coefficient determined approximately was 900 +/- 100 M "1 cm " 1 (273nm, methanol).
- Baccatina III was soluble at the concentrations used in 10mM sodium phosphate, ethylene glycol bis ( ⁇ -aminoethyl ether) -N, N, N ⁇ N'-tetraacetic acid (EGTA) 1 mM, 0.1 mM GTP, 6mM MgCl 2 , 3.4 M glycerol, (GAB buffer) pH 6.5 with 1% DMSO
- EGTA ethylene glycol bis ( ⁇ -aminoethyl ether) -N, N, N ⁇ N'-tetraacetic acid
- GTP ethylene glycol bis ( ⁇ -aminoethyl ether) -N, N, N ⁇ N'-tetraacetic acid
- GTP 0.1 mM GTP
- 6mM MgCl 2 6mM MgCl 2
- 3.4 M glycerol GAB buffer
- cross-linked microtubules have the same specificity, kinetics, and stoichiometry of Flutax-2 binding, as the non-cross-linked controls; they have a normal morphology under the electron microscope (D ⁇ az, JF, et al.).
- the cross-linked microtubules were dialyzed against GAB-0.1 mM nucleotide (GTP or GDP) for more than 16h cold in dialysis cassettes (Pierce) and kept frozen dropwise under liquid nitrogen, or at 4 ° C with 0 , 05% sodium azide.
- GTP or GDP GAB-0.1 mM nucleotide
- This method of conserving crosslinked microtubules, by dialysis against a preservation and cryopreservation buffer is claimed in the present invention.
- the cross-linked microtubules were used within a half-life from the preparation A fluorescence micrograph of these microtubules with Flutax-2 is shown in Fig. 1. 3. Fluorescence and anisotropy spectroscopy measurements Fluorescence spectra were obtained corrected with a Fluorolog-3-221 photon counting instrument (Jobin Yvon-Spex, Longiumean, France), with an emission bandwidth of 5nm and excitation of 1 ⁇ m, at 25 ° C.
- Fluorometric concentration measurements were made with a Shimadzu RF-540 spectrofluorometer Anisotropy spectra and measurements were collected in Fluorolog's T-format mode with vertical polarized excitation mind and s and corrected for the sensitivity of each channel with horizontally polarized excitation (Lackowicz JR). Multiple anisotropy measurements were performed with a PolarStar microplate reader (BMG Labtechnologies, Offenburg, Germany) at 25 ° C. The solutions were excited with 200 pulses of vertically polarized light (485-P bandpass filter, 480-492nm) and the emission was analyzed simultaneously with vertical and horizontal polarization filters (520-P bandpass, 515-550nm) .
- the sensitivity of the two channels was adjusted to give the anisotropy value of free Flutax-2 (0.055, polarization 0.080; GAB buffer at 25 ° C) in cavities containing Flutax-2 and not microtubules.
- the white values of wells with microtubules and without Flutax-2, the fluorescence intensity values were subtracted (whites typically accounted for less than 4% of the measurement).
- Flutax binding to microtubules Flutax-2 (50nM) was first titrated with increasing concentrations of binding sites provided by cross-linked microtubules, in GAB buffer at 25C.
- the bound Flutax-2 fraction is:
- [F] b / [F] 0 (r - r min ) / (r ma ⁇ -r m m) [1]
- [F] 6 and [F] o are total and joined concentrations of Flutax-2 respectively
- r is fluorescence anisotropy measured with the spectrofluorometer
- the value of r m ⁇ n is 0.055
- the value of r ⁇ x was an adjustable parameter. Assuming a one-to-one binding, the concentration of free binding sites [S] is:
- Control measurements with microtubule binding sites blocked by 10 ⁇ M paclitaxel gave r values very close to m n n , within a range [S] 0 of 0 to 100 nM.
- the cross-linked microtubules 50-1 OOnM total tubulin) were then titrated with known concentrations of Flutax-
- concentration of free Flutax-2 is:
- the ligands to be tested were added in small volumes of DMSO (final DMSO concentration 2% v / v) to make the desired duplicate concentrations. It was also found that paclitaxel did not adsorb to the plate during the test, using 3 H-Paclitaxel and a scintillation counter. Cavities without protein and without Flutax-2 were included for calibration and background measurements respectively (see anisotropy measurements above). The plates were agitated by rotation for 10 minutes and measured twice within 30-90 minutes after equilibration at 25 ° C in the microplate reader. Flutax-2 anisotropy data was calculated using the evaluation software (BMG) and plotted versus the total competitor concentration.
- BMG evaluation software
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epoxy Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES02735435T ES2287280T3 (es) | 2001-07-20 | 2002-05-31 | Metodo de deteccion y evaluacion de compuestos mimeticos de placlitaxel. |
CA002454396A CA2454396A1 (en) | 2001-07-20 | 2002-05-31 | Method of detecting and analysing paclitaxel-mimetic compounds |
EP02735435A EP1420249B1 (en) | 2001-07-20 | 2002-05-31 | Method of detecting and analysing paclitaxel-mimetic compounds |
DE60220286T DE60220286D1 (de) | 2001-07-20 | 2002-05-31 | Verfahren zum nachweis und zur analyse von paclitaxel imitierenden verbindungen |
US10/761,150 US7476511B2 (en) | 2001-07-20 | 2004-01-20 | Method of detecting and analyzing paclitaxel-mimetic compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP200101710 | 2001-07-20 | ||
ES200101710A ES2180453B1 (es) | 2001-07-20 | 2001-07-20 | Metodo de deteccion y evaluacion de compuestos mimeticos de paclitaxel. |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/761,150 Continuation US7476511B2 (en) | 2001-07-20 | 2004-01-20 | Method of detecting and analyzing paclitaxel-mimetic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003008965A1 true WO2003008965A1 (es) | 2003-01-30 |
Family
ID=8498472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2002/000262 WO2003008965A1 (es) | 2001-07-20 | 2002-05-31 | Metodo de deteccion y evaluacion de compuestos mimeticos de paclitaxel |
Country Status (7)
Country | Link |
---|---|
US (1) | US7476511B2 (es) |
EP (1) | EP1420249B1 (es) |
AT (1) | ATE363071T1 (es) |
CA (1) | CA2454396A1 (es) |
DE (1) | DE60220286D1 (es) |
ES (2) | ES2180453B1 (es) |
WO (1) | WO2003008965A1 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10399964B2 (en) | 2017-03-30 | 2019-09-03 | The University Of Kansas | Coumarin-linked taxanes for detection and circumvention of cellular efflux |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5340724A (en) * | 1991-04-25 | 1994-08-23 | The Upjohn Company | Use of taxol-dependent cells to identify and isolate taxol-like compounds |
WO1994020134A1 (en) * | 1993-03-03 | 1994-09-15 | The Trustees Of Columbia University In The City Of New Yrok | An endogenous taxol-like substance in human serum, monoclonal antibodies directed thereto, and methods of assaying therefor |
WO1997019938A1 (es) * | 1995-11-29 | 1997-06-05 | Consejo Superior Investigaciones Cientificas | Derivados fluorescentes de paclitaxel y docetaxel con actividad antineoplasica, metodo para obtenerlos y sus aplicaciones |
WO1999053295A1 (en) * | 1998-04-14 | 1999-10-21 | The Regents Of The University Of California | Assays for the detection of microtubule depolymerization inhibitors |
WO2000056894A1 (en) * | 1999-03-23 | 2000-09-28 | Cytoclonal Pharmaceutics, Inc. | Fungal beta-tubulin genes |
-
2001
- 2001-07-20 ES ES200101710A patent/ES2180453B1/es not_active Expired - Fee Related
-
2002
- 2002-05-31 EP EP02735435A patent/EP1420249B1/en not_active Expired - Lifetime
- 2002-05-31 WO PCT/ES2002/000262 patent/WO2003008965A1/es active IP Right Grant
- 2002-05-31 DE DE60220286T patent/DE60220286D1/de not_active Expired - Lifetime
- 2002-05-31 AT AT02735435T patent/ATE363071T1/de not_active IP Right Cessation
- 2002-05-31 ES ES02735435T patent/ES2287280T3/es not_active Expired - Lifetime
- 2002-05-31 CA CA002454396A patent/CA2454396A1/en not_active Abandoned
-
2004
- 2004-01-20 US US10/761,150 patent/US7476511B2/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5340724A (en) * | 1991-04-25 | 1994-08-23 | The Upjohn Company | Use of taxol-dependent cells to identify and isolate taxol-like compounds |
WO1994020134A1 (en) * | 1993-03-03 | 1994-09-15 | The Trustees Of Columbia University In The City Of New Yrok | An endogenous taxol-like substance in human serum, monoclonal antibodies directed thereto, and methods of assaying therefor |
WO1997019938A1 (es) * | 1995-11-29 | 1997-06-05 | Consejo Superior Investigaciones Cientificas | Derivados fluorescentes de paclitaxel y docetaxel con actividad antineoplasica, metodo para obtenerlos y sus aplicaciones |
WO1999053295A1 (en) * | 1998-04-14 | 1999-10-21 | The Regents Of The University Of California | Assays for the detection of microtubule depolymerization inhibitors |
WO2000056894A1 (en) * | 1999-03-23 | 2000-09-28 | Cytoclonal Pharmaceutics, Inc. | Fungal beta-tubulin genes |
Non-Patent Citations (3)
Title |
---|
ANDREU J.M., BARASOAIN I.: "The interaction of Baccatin III with the taxol binding site of microtubules determined by a homogeneous assay with fluorescent Taxoid", BIOCHEMISTRY, vol. 40, no. 40, 9 October 2001 (2001-10-09), pages 11975 - 11984, XP002976063 * |
DIAZ J.F. ET AL: "Molecular recognition of Taxol by microtubules: kinetics and thermodynamics of binding of fluorescent taxol derivatives to an exposed site", THE JOURNAL OF THE BIOLOGICAL CHEMISTRY, vol. 275, no. 34, 25 August 2000 (2000-08-25), pages 26265 - 26276, XP002976064 * |
NEUMANN T. ET AL: "Determination of the net exchange rate of tubulin dimer in steady-state microtubules by fluorescence correlation spectroscopy", BIOLOGICAL CHEMISTRY, vol. 382, no. 3, March 2001 (2001-03-01), pages 387 - 391, XP008002264 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10399964B2 (en) | 2017-03-30 | 2019-09-03 | The University Of Kansas | Coumarin-linked taxanes for detection and circumvention of cellular efflux |
Also Published As
Publication number | Publication date |
---|---|
ES2180453B1 (es) | 2004-05-01 |
ATE363071T1 (de) | 2007-06-15 |
US20040203082A1 (en) | 2004-10-14 |
EP1420249A1 (en) | 2004-05-19 |
EP1420249B1 (en) | 2007-05-23 |
DE60220286D1 (de) | 2007-07-05 |
ES2287280T3 (es) | 2007-12-16 |
ES2180453A1 (es) | 2003-02-01 |
US7476511B2 (en) | 2009-01-13 |
CA2454396A1 (en) | 2003-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yu et al. | Carbon-dot-based ratiometric fluorescent sensor for detecting hydrogen sulfide in aqueous media and inside live cells | |
Wang et al. | A rapid-response fluorescent probe for the sensitive and selective detection of human albumin in plasma and cell culture supernatants | |
Hinrichs et al. | Tau protein diffuses along the microtubule lattice | |
Xu et al. | A selective near-infrared fluorescent probe for singlet oxygen in living cells | |
Zhou et al. | Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine | |
Bijari et al. | Spectroscopic study of interaction between osthole and human serum albumin: Identification of possible binding site of the compound | |
ES2665953T3 (es) | Inmunoensayos que emplean reactivos quimioluminiscentes no particulados | |
Yeggoni et al. | Elucidating the binding interaction of andrographolide with the plasma proteins: biophysical and computational approach | |
Kita et al. | Marine natural products that interfere with multiple cytoskeletal protein interactions | |
Sun et al. | Rational design of biotinylated probes: fluorescent turn-on detection of (strept) avidin and bioimaging in cancer cells | |
ES2368669T3 (es) | Ensayo genérico de detección de actividad quinasa/fosfatasa con una única lectura. | |
Kotera et al. | A doubly responsive probe for the detection of Cys4-tagged proteins | |
Tatlidil et al. | Physiological concentrations of albumin favor drug binding | |
Truxal et al. | Directly functionalized cucurbit [7] uril as a biosensor for the selective detection of protein interactions by 129Xe HyperCEST NMR | |
Li et al. | A dual-response NIR probe reveals positive correlation between biothiols and viscosity under cellular stress change | |
Raza et al. | Molecular mechanism of tobramycin with human serum albumin for probing binding interactions: multi-spectroscopic and computational approaches | |
Roy et al. | Effects of urea, metal ions and surfactants on the binding of baicalein with bovine serum albumin | |
Bozilovic et al. | Novel, highly potent PROTACs targeting AURORA-A kinase | |
ES2287280T3 (es) | Metodo de deteccion y evaluacion de compuestos mimeticos de placlitaxel. | |
Liu et al. | Comparing the effects of Fe (III) and Cu (II) on the binding affinity of erlotinib to bovine serum albumin using spectroscopic methods | |
Ekambaram et al. | PIM kinase-responsive microsecond-lifetime photoluminescent probes based on selenium-containing heteroaromatic tricycle | |
ES2360699T3 (es) | Inmunoensayo basado en la inhibición enzimática. | |
US10399964B2 (en) | Coumarin-linked taxanes for detection and circumvention of cellular efflux | |
Bapli et al. | Interaction of a hydrophilic molecule with bovine serum albumin: A combined multi-spectroscopic, microscopic and isothermal calorimetric study in the presence of graphene oxide | |
Kriisa et al. | Inhibition of CREB Phosphorylation by Conjugates of Adenosine Analogues and Arginine‐Rich Peptides, Inhibitors of PKA Catalytic Subunit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2454396 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10761150 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002735435 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002735435 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002735435 Country of ref document: EP |